DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Yu ML, Hung CH, Huang YH. et al.
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for the treatment of HCV genotype 1b infection without baseline NS5A resistance-associated variants (DARING).
J Formos Med Assoc 2019;
118: 556-564
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.